Table 1 Baseline characteristics of the study population.

From: Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL

Characteristic

N = 161

Age (years)

46 [18–87]

WBC at diagnosis (×109/L)

7.6 [0.3–698.9]

ALL subtype

 Ph-positive

51 (32)

 Ph-negative

110 (68)

Frontline therapy

 Hyper-CVAD-based

69 (43)

 Mini-hyper-CVD-based

45 (28)

 Chemotherapy-free

47 (29)

Cytomolecular features (Ph-negative subgroup only, N = 110)

Cytogenetics

 Diploid

30 (27)

 High hyperdiploidy

3 (3)

 Low hypodiploidy / near triploidy

11 (10)

 KMT2A rearranged

6 (5)

 Complex

8 (7)

 Miscellaneous

31 (28)

 Insufficient metaphases

20 (19)

Ph-like ALL

23/107 (21)

 CRLF2 abnormalitya

17/107 (16)

 Non-CRLF2 abnormality

6/107 (6)

TP53-mutated

28/109 (26)

Poor-risk cytomolecular feature(s)b

59 (54)

  1. WBC white blood cell, hyper-CVAD hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose methotrexate and cytarabine, mini-hyper-CVD low-dose hyperfractionated cyclophosphamide, vincristine and dexamethasone alternating with methotrexate and cytarabine, Ph Philadelphia chromosome.
  2. aCRLF2 overexpression by flow cytometry and/or established rearrangement.
  3. bIncludes: low hypodiploidy/near triploidy, complex cytogenetics (i.e. presence of >5 chromosomal abnormalities), KMT2A rearranged, Ph-like ALL, and/or TP53 mutation.
Back to article page